Drug Trial Radar · NCT05213624
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
May 3, 2022
Primary completion
Jan 3, 2025
Study completion Jan 3, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day. Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits. Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.
Conditions
- Kidney Disease, Chronic
Interventions
BI 764198Drug
One single capsule of 20 milligrams (mg), 40 mg, or 80 mg of BI 764198 orally, once a day.
PlaceboDrug
One single capsule of placebo matching BI 764198 orally, once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12Time frame: At baseline and Week 12.
- Relative Change From Baseline at Week 12 of 24-hour Urine Protein Creatinine Ratio (UPCR)Time frame: At baseline and at Week 12.
Locations
54 sites in 10 countries. Site status is shown where the registry gives one.
Nephrology Consultants, LLC
Huntsville, Alabama
University of California San Francisco
San Francisco, California
Valiance Clinical Research-South Gate-67878
South Gate, California
Valiance Clinical Research-Tarzana-68237
Tarzana, California
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Elixia Fort Lauderdale, LLC
Fort Lauderdale, Florida
South Florida Research Institute
Lauderdale Lakes, Florida
Total Research Group, LLC
Miami, Florida
Emory Children's Center
Atlanta, Georgia
NANI Research, LLC
Oak Brook, Illinois
University of Michigan Health System
Ann Arbor, Michigan
Jacobi Medical Center
The Bronx, New York
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Texas Tech University Health Sciences Center-Amarillo-63885
Amarillo, Texas
Dallas Nephrology Associates Medical Clinic
DeSoto, Texas
Prolato Clinical Research Center-Houston-68087
Houston, Texas
Liverpool Hospital
Liverpool, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Griffith Health
Southport, Queensland, Australia
Sunshine Hospital
AT Albans, Victoria, Australia
UZ Leuven
Leuven, Belgium
Fu Yang people's Hospital
Fuyang, China
Guangdong Provincial People's Hospital
Guangzhou, China
The First Afiliated Hospital, Sun Yet-sen University
Guangzhou, China
Zhejiang Province People's Hospital
Hangzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
The First People's Hospital of Nanning
Nanning, China
Tongren hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Shanghai Fifth People's Hospital affiliated to Fudan University
Shanghai, China
HOP Pellegrin
Bordeaux, France
HOP Bicêtre
Le Kremlin-Bicêtre, France
HOP Hôtel-Dieu
Nantes, France
Universitätsklinikum Köln (AöR)
Cologne, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.